

9:00 a.m.	Welcome Message: Prof. Maciej Banach
ILEP Guests - Invited Honorary Lecture	
9:00 a.m.	New guidelines on cardiovascular prevention and a focus on old and new risk factors
9:20 a.m.	Prof. Naveed Sattar Glasgow, UK
Session 1: Ongoing Discussion on the Optimal Risk Stratification in Patients at CVD Risk Chair: Prof. Arrigo F.G. Cicero	
9:20 a.m.	New (bio)markers in the modern cardiovascular disease diagnosis and management
9:35 a.m.	Prof. Dan Gaita Timisoara, Romania
9:35 a.m.	Cardiovascular Risk Assessment: From Global Risk Assessment to Subclinical Atherosclerosis. Role of CAC scoring
9:50 a.m.	Prof. Nathan D. Wong Irvine, CA, USA
9:50 a.m.	Redefining cardiovascular risk in type 2 diabetes
10:05 a.m.	Prof. Niki Katsiki Thessaloniki, Greece
10:05 a.m.	Utility of genetic testing in CVD prevention
10:20 a.m.	Prof. Michal Vrablik Prague, Czechia
10:20 a.m.	Panel Discussion
10:35 a.m.	
Session 2: How Effectively Treat and Prevent Very High and Extremely High-Risk Patients? New Approaches, Innovative Tools. Chair: Prof. Dariusz Dudek	
10:35 a.m.	The role of therapy adherence and physicians' inertia in the optimal therapy of patients at very high CVD risk
10:50 a.m.	Prof. Zeljko Reiner Zagreb, Croatia
10:50 a.m.	Importance of combination therapy in FH patients - application vs availability
11:05 a.m.	Prof. Gustavs Latkovskis Riga, Latvia
11:05 a.m.	Session Pro/Contra
11:35 a.m.	2022 recommendations on prevention of first and recurrent cardiovascular events Early intensive approach – Prof. Maciej Banach, Lodz, Poland 2022 recommendations on prevention of first and recurrent cardiovascular events Stepwise approach – Prof. Lale Tokgözoğlu, Ankara, Turkey
11:35 a.m.	The Role of Digital Health in Lipid Management and Cardiovascular Disease Prevention
11:50 a.m.	Prof. Seth S. Martin Baltimore, USA
11:50 a.m.	Panel Discussion
12:05 p.m.	
ILEP Guests - Invited Honorary Lecture	
12:05 p.m.	Epigenetic modifications in cardiometabolic disorders as a way for effective therapy and prevention
12:25 p.m.	Prof. Francesco Paneni Zurich, Switzerland

Session 3: Effective Prevention in Real-Life Practice Chair: Prof. Richard Ceska	
12:25 p.m. 12:40 p.m.	Universally accessible Primary CVD Prevention Programme we execute in Slovenia now for almost 20 years... Prof. Zlatko Fras Ljubljana, Slovenia
12:40 p.m. 12:55 p.m.	The prevalence of dyslipidemia and achievement of therapeutic goals among primary care patients in Poland – results from the LIPIDOGRAM 2015 study Prof. Jacek Jozwiak Opole, Poland
12:55 p.m. 13:10 p.m.	FH in the Arabian Gulf region – new real-world data on diagnosis and therapy Prof. Fahad Alnouri Riyadh, Saudi Arabia
13:10 p.m. 13:25 p.m.	Lp(a) and Lipoprotein Apheresis – the current state of knowledge and real-life experience Prof. Claudia Stefanutti Rome, Italy
13:35 p.m. 13:50 p.m.	Panel Discussion
Session 4: Comprehensive Prevention, Not Only Lipids Stupid! Chair: Prof. Matteo Pirro	
13:50 p.m. 14:05 p.m.	Premature MI – lipids? Lp(a)? genetics? - an attempt at diagnostic and therapeutic optimal management pathway Prof. Peter P. Toth Chicago, USA
14:05 p.m. 14:20 p.m.	Prediction of the rate of progression of atherosclerotic changes - role of inflammation Prof. Arman Postadzhiyan Sofia, Bulgaria
14:20 p.m. 14.35 p.m.	Atherogenic dyslipidemia and residual cardiovascular risk: novel therapeutical approaches Prof. Manfredi Rizzo Palermo, Italy
14:35 p.m. 14:50 p.m.	New/innovative approaches for the treatment of severe hypertriglyceridemia Prof. Ioanna Berthold Cologne, Germany
14:50 p.m. 15:05 p.m.	Panel Discussion
ILEP Guests – Invited Honorary Lecture	
15:05 p.m. 15:25 p.m.	What is the best diet for effective CVD prevention? Prof. Erin Michos Baltimore, USA

Session 5: Dyslipidemia as a Risk Factor Worsening the Course of Other Chronic Diseases

Chair: Prof. Carlos Escobar

15:25 p.m. - 15:40 p.m. Can antidiabetic therapy affect dyslipidemia, and can lipid reduction optimize the treatment of diabetes?

Prof. Gani Bajraktari
Prishtina, Kosovo

15:40 p.m. - 15:55 p.m. NAFLD and vascular risk - what we know and what we should know?

Prof. Dimitri P. Mikhailidis
London, UK

15:55 p.m. - 16:10 p.m. Ventriculo-arterial coupling - this is the road to... heart failure

Prof. Dragos Vinereanu
Bucharest, Romania

16:10 p.m. - 16:25 p.m. Vascular disease and its effects on cognition - how to treat to improve both?

Prof. Patrick M. Moriarty
Kansas City, USA

16:25 p.m. - 16:40 p.m. Panel Discussion

CVD Prevention RoundTable: What are the largest unmet needs and challenges in CVD prevention in Europe and worldwide - from education, healthcare system organization, drug availability to innovative tools and coordinated care.

16:40 p.m. Moderator: Prof. Maciej Banach

17:55 p.m. Experts: Prof. Ioanna Berthold, Prof. Zeljko Reiner, Prof. Michal Vrablik, Prof. Peter P. Toth, Prof. Niki Katsiki, Magdalena Daccord.

17:55 p.m. - 18:00 a.m. Closing Message: Prof. Maciej Banach